Show simple item record

dc.contributor.authorKaymakoglu, Sabahattin
dc.contributor.authorYenice, N
dc.contributor.authorOzbay, Gülşen
dc.contributor.authorTabak, F
dc.contributor.authorOzaras, Reşat
dc.contributor.authorSenturk, H
dc.contributor.authorErsoz, G
dc.contributor.authorBozkaya, H
dc.contributor.authorAkdogan, M
dc.contributor.authorMert, A
dc.contributor.authorBozdayi, M
dc.date.accessioned2021-03-02T20:45:51Z
dc.date.available2021-03-02T20:45:51Z
dc.date.issued2003
dc.identifier.citationSenturk H., Ersoz G., Ozaras R., Kaymakoglu S., Bozkaya H., Akdogan M., Mert A., Bozdayi M., Tabak F., Yenice N., et al., "Interferon-alpha(2b) induction treatment with or without ribavirin in chronic hepatitis C - A multicenter, randomized, controlled trial", DIGESTIVE DISEASES AND SCIENCES, cilt.48, sa.6, ss.1124-1129, 2003
dc.identifier.issn0163-2116
dc.identifier.othervv_1032021
dc.identifier.otherav_03876b60-bc47-4ef6-9c16-a406fe25bb2a
dc.identifier.urihttp://hdl.handle.net/20.500.12627/8323
dc.identifier.urihttps://doi.org/10.1023/a:1023725014751
dc.description.abstractWe aimed to compare the efficacy of interferon-alpha(2b) (IFN) induction treatment in combination with ribavirin to IFN induction alone in chronic hepatitis C. In total, 125 patients (66 male, 59 female, mean age: 48 +/- 9, range: 21-70) were enrolled and randomized into two arms.In the first, patients received 5 MU/day of IFN for 4 weeks followed by 3 MU/day for the next 4 weeks. Treatment was continued with 3 MU three times a week IFN for an additional 40 weeks. Ribavirin was administered 1000-1200 mg/day according to the body weight for the entire 48-week period. In the second arm, patients received placebo in addition to IFN. Fifty-nine patients were placed in the ribavirin arm and 66 in placebo arm. All patients were genotype 1. At week 48, 24/66 (36%) from the placebo and 31/59 (52%) from the ribavirin group responded (P > 0.05). However, during the 24-week untreated follow-up period, 13/24 (54%) from the placebo, and 8/31 (26%) from the ribavirin group relapsed (P = 0.002.), resulting in a sustained virologic response (SVR) rate of 17% in the placebo and 39% in the ribavirin group (P = 0.005.) In conclusion, IFN induction treatment in combination with ribavirin is superior to IFN induction treatment alone in genotype 1 patients, and the SVR rate of 39% is encouraging.
dc.language.isoeng
dc.subjectGastroenteroloji-(Hepatoloji)
dc.subjectİç Hastalıkları
dc.subjectDahili Tıp Bilimleri
dc.subjectSağlık Bilimleri
dc.subjectTıp
dc.subjectKlinik Tıp (MED)
dc.subjectKlinik Tıp
dc.subjectGASTROENTEROLOJİ VE HEPATOLOJİ
dc.titleInterferon-alpha(2b) induction treatment with or without ribavirin in chronic hepatitis C - A multicenter, randomized, controlled trial
dc.typeMakale
dc.relation.journalDIGESTIVE DISEASES AND SCIENCES
dc.contributor.department, ,
dc.identifier.volume48
dc.identifier.issue6
dc.identifier.startpage1124
dc.identifier.endpage1129
dc.contributor.firstauthorID41041


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record